3D Tissue Models

View Profile

Speaking/Presenting-Abstract/Poster at Mtg

Topic Authors / presenters Event name Event date
1. Mechanisms of trastuzumab-resistance in SKBR3 breast cancer cells. NIH Research Festival October, 2000
2. Cdc42 as a potential therapeutic target for the reduction of cellular proliferation and migration as measured in MDA-MB-231 breast cancer cells The 2005 NIH Research Festival October, 2000
3. The role of Cdc42 in the development of human breast cancer. The 2005 NIH Research Festival October, 2000
4. Reduction of Cdc42 by siRNA leads to reduced EGFR protein levels, reduced cell proliferation and reduced cell migration The NIH Immunology Interest Group (IIG) retreat September, 2000
5. Cdc42 regulates E-cadherin ubiquitination and degradation. Regulation and function of small GTPases. FASEB summer meeting July, 2000
6. Rac1 contributes to trastuzumab-resistance of breast cancer cells. 100th Annual Meeting Colorado Convention Center April, 2000
7. Growth and motility inhibition of breast cancer cells by EGFR degradation is correlated with inactivation of Cdc42 AACR annual conference April, 2000
8. Reduction in cellular proliferation and migration in MDA-MB-231 breast cancer cells using Cdc42 specific siRNA FDA Science Forum April, 2000
9. The IOTF Fellowship: A new perspective in regulatory affairs of drug development. The WCBP 2007 Symposium January, 2000

Site wide Speaking/Presenting-Abstract/Poster at Mtg

Presentation Event Month, Year
Trastuzumab Conjugate for the Treatment of Trastuzumab-Resistant Human Breast Cancer: Increasing Magnitude and Duration of Response Antibody Optimization May, 2010

About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.